Dr. Charles Lynde

Dermatologist, Markham, ON

Dr. Charles Lynde is an Associate Professor in the Department of Medicine at the University of Toronto and holds a clinical teaching position at the University Health Network. He is the Medical Director of Lynde Institute for Dermatology and Lynderm Research. The Lynde Institute for Dermatology is a full service, interdisciplinary dermatology clinic. After receiving his B.Sc. and MD, degrees at the University of Toronto, Dr. Lynde studied Dermatology at the University of British Columbia and the University of Toronto, receiving his Board Certification (Canada and USA) in 1983.

Lynderm Research is under the guidance of Dr. Lynde as principal investigator for more than 30 years and over 300 clinical trials and is actively involved in the management of psoriasis, rosacea, onychomycosis, acne and atopic dermatitis among other dermatological conditions. Dr. Lynde has authored over 200 peer-reviewed articles.

Dr. Lynde has served in various roles for the CDA and AAD, including President of the Canadian Dermatology Association. He is the Editor of the CDA eBulletin and sits on the editorial boards of several journals and provides extensive consulting as well as being on the advisory boards of many pharmaceutical companies. Dr. Lynde is a frequent guest speaker both nationally and internationally at various dermatological conferences. Recognizing the need for external education he is committed to the training of new and current healthcare professionals in his community and residents through the university program.

1:00 PM - 1:05 PM Plenary Session 1

Thursday NOV 11, 2021

Opening & Welcome

1:05 PM - 1:20 PM

Thursday NOV 11, 2021

The Evolution of Teledermatology: For the better?

Dermatologists have now universally had experience with teledermatology during the pandemic and gained an appreciation of the benefits and limitations. What comes next?

 

How do we improve the percentage of successful teleconsults in order to more appropriately utilize limited in-person capacity? In this talk we will discuss both emerging technical and patient pathway considerations for assessment and diagnosis of skin lesions and dermatological conditions.

1:20 PM - 1:35 PM Plenary Session 1

Thursday NOV 11, 2021

New Cutaneous Cancer Treatments

There has been a paradigm shift as to how we treat regional and metastatic cutaneous malignancies that is now being investigated to treat high risk local disease. This presentation will provide an overview of currently available systemic treatments for skin cancers. Additionally, it will review locoregional and topical therapies available or under investigation.

1:35 PM - 1:55 PM Plenary Session 1

Thursday NOV 11, 2021

Advancement in the Treatment of Metastatic Melanoma: A new targeted therapy

1:35 PM - 1:55 PM Plenary Session 1

Thursday NOV 11, 2021

Q&A

2:15 PM - 3:15 PM Pfizer Canada Open Session

Thursday NOV 11, 2021

Optimal use of Topical Treatment in AD – Tips for Clinical Practice Using Crisaborole


Objectives:

This open session aims to:

  • Review best clinical practices in topically treating AD patients
  • Explore optimal use of crisaborole in mild to moderate AD
  • Provide expert guidance for the real-world use of crisaborole ointment to improve patients’ outcomes

 

Summary:
Atopic dermatitis (AD) is a lifelong inflammatory skin condition associated with altered immune function and epidermal barrier dysfunction. Mild to moderate disease is usually controlled by behavioral measures such as skin care and avoidance of triggers and treatments such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and crisaborole, a phosphodiesterase-4 inhibitor (PDE4-I).

 

Evidence from the literature coupled with the panels' expert opinion, experiences and, key insights have given rise to the recommendations on optimal crisaborole ointment use for patients with mild-to-moderate AD. The ointment provides a good and safe alternative to TCS and TCI.

 

The presentation discusses best clinical practices in the topical treatment of mild to moderate AD patients and provides expert guidance for the real-world use of crisaborole ointment.

 

Atopic dermatitis is a chronic condition in which patients may oscillate between degrees of severity over time and may have different levels of severity in various skin areas at any one time. Therefore, the best treatment paradigms reflect a need for a range of products that target these different levels of severity.

 

Crisaborole is a nonsteroidal PDE4-I with demonstrated efficacy in patients aged three months and older with mild to moderate AD. It is a well-tolerated alternative to TCS or TCI and can be used on any body site. It may be especially beneficial for areas with thicker skin, such as hands and feet. There are no concerning safety signals associated with crisaborole; other than its possible burning sensation. Information and education on measures to avoid side effect can help optimize results and adherence.

 

Cases will be presented to illustrate best clinical practices in the topical treatment of mild to moderate AD patients with crisaborole.

4:00 PM - 7:00 PM MedX Health Advisory Board

Thursday NOV 11, 2021

MedX Health Advisory Board

MedX Health

9:00 AM - 9:45 AM Plenary Session 2

Friday NOV 12, 2021

Drug Update 2021

10:00 AM - 10:10 AM Plenary Session 2

Friday NOV 12, 2021

Q&A

10:15 AM - 10:45 AM Eucerin Open Presentation

Friday NOV 12, 2021

Principals of Basic Care for Xerosis

A structured symptom- and evidence-based approach including a road map for diagnosis and treatment of xerosis cutis. The session aims to raise awareness in terms of prevention and early treatment of this condition and may thus improve quality of life and prevent potential sequelae.

 

10:50 AM - 11:20 AM SkinCeuticals Open Presentation

Friday NOV 12, 2021

Beyond Sunscreen and Retinoids: Will Patients Benefit From An Antioxidant Serum?


The antioxidant treatment choices are numerous leading to confusion in product claims for patients and for clinicians, with a paucity of clinical data. Do patients really benefit from the use of antioxidants? Is every antioxidant serum the same? What clinical scenarios will provide optimal clinical outcomes?

 

Objectives:

  • Discuss the deleterious effects of free radicals on the skin and the aging process
  • Review the existing literature of use of antioxidants in skincare, providing insight to the question whether antioxidant serums actually influence the way our skin ages.
  • Discuss the importance of clinical data to support serum selection.
4:35 PM - 5:35 PM Bausch Open Session

Friday NOV 12, 2021

Treating moderate-to-severe plaque psoriasis to target: new and old concepts for topical and biologic therapies


Treat-to-target (T2T) refers to a clinical framework for managing chronic diseases that sets standards for assessing treatment goals and suggests treatment strategies if targets are not achieved. T2T recommendations in moderate-to-severe plaque psoriasis have been published by expert groups from around the world. In these, treatment target is usually defined by a single severity measure, targets vary between consensus groups, and there are few recommendations for modifying treatment if target is not achieved. In this symposium, we present a multi-dimensional, criteria-based, T2T model developed by Canadian dermatologists managing moderate-to-severe plaque psoriasis. Treatment modification strategies will be presented and discussed with a focus on optimizing or switching biologic treatments. As topical treatments as mainstays in managing psoriasis, their role within a T2T model will be discussed with consideration given to long-term data from recently published studies.

 

Objectives:

  • Introduce a Canadian criteria-based model for treatment targets in plaque psoriasis.
  • Review evidence supporting treatment strategies for when target is not achieved, with a focus on switching biologics.
  • Consider a treat-to-target approach in the early management of plaque psoriasis and critically appraise new clinical data on the long-term management of plaque psoriasis using topical treatments
8:45 AM - 9:30 AM Bausch Open Presentation

Saturday NOV 13, 2021

Advances in Acne Vulgaris: Updates in topical retinoid therapy


Objectives:

  • Describe new developments in topical retinoid treatments for acne vulgaris
  • Recognize key considerations around vehicles for topical treatments in dermatology
  • Integrate data on safety and efficacy of retinoids into the treatment of acne vulgaris in day-to-day practice

Summary description of the session:

Join us for an international expert panel discussion that will address new advances in topical retinoid treatment of acne vulgaris. A new formulation of a topical retinoid has been developed, incorporating recent developments in vehicle technology, to address shortcomings of older retinoid formulations. Acne experts from the US and Canada will discuss the clinical trial data, the value of this innovation, and how it fits into their day-to-day practice.

12:25 PM - 12:35 PM Rapid Fire Presentations

Saturday NOV 13, 2021

Update on Cosmetic Dermatology

In this rapid fire session, we will review new additions to our cosmetic therapeutic armamentarium and up and coming products that are in development.

12:45 PM - 1:15 PM La Roche Posay Open Presentation

Saturday NOV 13, 2021

Latest Updates in the Management of Dry Skin-related Dermatoses

La Roche Posay logo
The burden of skin disease and its symptoms can significantly impact patients' quality of life. Ongoing care for patients with skin conditions can be optimized by proper adjunctive care, which can have a significant impact on patient compliance and treatment outcomes.

Objectives:

  1. Discuss the importance of adjunctive therapy in the management of skin conditions.
  2. Review the pathophysiology of atopic dermatitis and contact dermatitis.
  3. Evaluate adjunctive therapy impact on atopic dermatitis and contact dermatitis
  4. Discuss how adequate choices of adjunctive therapy can significantly impact patients' quality of life
1:20 PM - 2:20 PM UCB Open Session

Saturday NOV 13, 2021

A Sneak Peek at Bimekizumab: A Review of the Data


Dr. Ron Vender and Dr. Kerri Purdy will examine the efficacy and safety of bimekizumab in patients with moderate to severe psoriasis. At the conclusion of this session, physicians will be informed about: bimekizumab's clinical trial efficacy and safety data in patients with moderate to severe psoriasis; and Canadian investigators' first-hand experience with bimekizumab in patients with moderate to severe psoriasis.

2:25 PM - 3:25 PM Sun Pharma Open Session

Saturday NOV 13, 2021

Illumya™ is here for your patients, long SUNny days ahead


Following a presentation of tildrakizumab efficacy and safety data, participants will engage in open discussion to discuss how tildrakizumab may fill an unmet need in moderate-to-severe PsO, its place in treatment compared to IL-23 inhibitors, and best clinical practice in the management of PsO patients.

Objectives:

  1. Understand & gain insights into how Canadian dermatologists currently manage patients with moderate-to-severe psoriasis;
  2. Identify how tildrakizumab can fulfill an unmet need with Canadian dermatologists;
  3. Share clinical experience and best practices on what outcome measures could facilitate clinical decisions in the management of patients with psoriasis.
3:25 PM - 3:45 PM Closing Comments

Saturday NOV 13, 2021

Closing Comments

4:00 PM - 7:00 PM CeraVe Ad Board

Saturday NOV 13, 2021

CeraVe Skin of Ethnic Variations Advisory Board

Cerave logo